1. Home
  2. FSEA vs LUNG Comparison

FSEA vs LUNG Comparison

Compare FSEA & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Seacoast Bancorp Inc.

FSEA

First Seacoast Bancorp Inc.

HOLD

Current Price

$16.83

Market Cap

52.7M

Sector

Finance

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.44

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FSEA
LUNG
Founded
1890
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Industrial Specialties
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
52.7M
57.9M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
FSEA
LUNG
Price
$16.83
$1.44
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$5.38
AVG Volume (30 Days)
23.9K
330.3K
Earning Date
05-12-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.01
52 Week Low
$10.13
$1.13
52 Week High
$16.90
$3.88

Technical Indicators

Market Signals
Indicator
FSEA
LUNG
Relative Strength Index (RSI) 77.51 47.35
Support Level $16.60 $1.36
Resistance Level N/A $1.45
Average True Range (ATR) 0.05 0.11
MACD -0.15 -0.02
Stochastic Oscillator 44.83 23.29

Price Performance

Historical Comparison
FSEA
LUNG

About FSEA First Seacoast Bancorp Inc.

First Seacoast Bancorp Inc is the savings and loan holding company. The banks business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank, in one- to four-family residential real estate loans, commercial real estate and multi-family real estate loans, acquisition, development and land loans, commercial and industrial loans, home equity loans and lines of credit and consumer loans. It operates in single segment of Banking Services.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: